Clinical Trials Browser

Phase 2 × pyrotinib × 30 days × Clear all

NCT05582499 2026-05-28

FASCINATE-N

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07610720 2026-05-28

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms